Welcome to our dedicated page for Danaher news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher stock.
Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Danaher (NYSE: DHR) will host its First Quarter 2026 earnings conference call on Tuesday, April 21, 2026 at 8:00 a.m. ET.
The one-hour webcast will include discussion of financial results and outlook, a slide presentation, and a replay; earnings materials will be posted to the Investors section beginning at 6:00 a.m. ET on the call date.
Danaher (NYSE: DHR) announced a regular quarterly cash dividend of $0.40 per share, payable April 24, 2026, to shareholders of record on March 27, 2026.
The Board of Directors approved the dividend on February 24, 2026; the payment and record dates are specified for shareholder planning.
Danaher (NYSE: DHR) announced that President and CEO Rainer M. Blair will present at the TD Cowen Healthcare Conference in Boston on March 3, 2025 at 1:50 p.m. ET. The presentation will be webcast and accessible via Danaher's Investors site under Events & Presentations.
Masimo (Nasdaq: MASI) agreed to be acquired by Danaher (NYSE: DHR) for $180.00 per share in cash, representing total consideration of $9.9 billion. The boards of both companies unanimously approved the transaction.
Masimo will operate as a standalone business unit and brand within Danaher’s Diagnostics segment and is expected to close in the second half of 2026, subject to regulatory approvals. Masimo will report Q4 and full‑year 2025 results on Feb 26, 2026 but will not host an earnings call.
Danaher (NYSE: DHR) entered a definitive agreement to acquire Masimo (NASDAQ: MASI) for $180 per share in cash, implying an approximate $9.9 billion enterprise value including assumed debt and net of cash. The deal values Masimo at ~18x estimated 2027 EBITDA (15x including expected synergies).
Danaher expects Masimo to generate >$530 million EBITDA in 2027, deliver >$125 million annual cost synergies and >$50 million annual revenue synergies by year five, and be accretive to adjusted diluted EPS by $0.15–$0.20 in year one and ~ $0.70 in year five. Closing is anticipated in H2 2026, subject to regulatory clearances and Masimo shareholder approval.
Danaher (NYSE: DHR) reported Q4 2025 net earnings of $1.2 billion ($1.66 per diluted share) and full‑year net earnings of $3.6 billion ($5.03 per diluted share).
Q4 revenue rose 4.5% to $6.8 billion; FY2025 revenue was $24.6 billion (+3.0%). Non‑GAAP adjusted EPS grew ~4% Q4 and 4.5% FY. Operating cash flow was $2.1 billion in Q4 and $6.4 billion for FY; non‑GAAP free cash flow was $1.8 billion Q4 and $5.3 billion FY.
The company launched new products across bioprocessing, mass spectrometry, and diagnostics and initiated FY2026 guidance: core revenue +3–6% and adjusted EPS $8.35–8.50.
Danaher (NYSE: DHR) announced that CEO Rainer M. Blair will comment on fourth quarter 2025 results at the J.P. Morgan Healthcare Conference on Jan 13, 2026 at 11:15 a.m. PT, with the presentation webcast on the company's Investors site.
For Q4 2025, Danaher expects estimated revenues to increase in the mid-single digit percent range year-over-year and non-GAAP core revenue growth toward the high end of its prior low-single digit guidance. For full-year 2025, the company expects non-GAAP adjusted diluted EPS toward the high end of its guidance range of $7.70 to $7.80. The company reiterated strength in Bioprocessing and better-than-expected Life Sciences and Diagnostics revenue in Q4.
Danaher (NYSE: DHR) said its President and Chief Executive Officer, Rainer M. Blair, will present at the J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026 at 11:15 a.m. PT.
The presentation will be simultaneously webcast and accessible from the company's Investors site under Events & Presentations at www.danaher.com.
Danaher (NYSE: DHR) will webcast its Fourth Quarter 2025 earnings conference call on Wednesday, January 28, 2026 at 8:00 a.m. ET, with an expected duration of about one hour.
The company will discuss financial performance and future expectations. The live webcast and accompanying slide presentation will be available in the Investors > Events & Presentations section at www.danaher.com. Webcast slides, the earnings press release, and related materials will be posted beginning at 6:00 a.m. ET on the day of the call.
Dial-in access: 800-245-3047 (U.S.) or +1 203-518-9765 (outside U.S.); Conference ID: DHRQ425. A replay of the webcast and call will be available after the presentation; the call replay remains available until February 11, 2026.
Danaher (NYSE: DHR) announced a regular quarterly cash dividend of $0.32 per share. The dividend is payable on January 30, 2026 to holders of record on December 26, 2025.